The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: The phase 3 randomized LEVEL, GETNE-T2217 trial.
 
Alejandro Garcia-Alvarez
Speakers' Bureau - Angelini Pharma; Eisai; Eisai Europe
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis; Advanz Pharma; Advanz Pharma; Amgen; Eisai Europe; Ipsen; Pfizer
 
Rocio Garcia-Carbonero
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; Astellas Pharma; AstraZeneca (I); Bayer; BMS; Boehringer Ingelheim; Esteve; Gilead Sciences (I); Hutchmed; Ipsen; Lilly (I); Merck; Midatech Pharma; Mirati Therapeutics (I); MSD; Pfizer (I); PharmaMar; Roche (I); Sanofi (I); Servier; Takeda
Research Funding - BMS (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis; Esteve; Ipsen; Merck; MSD
 
Beatriz Anton-Pascual
Consulting or Advisory Role - Advanced Accelerator Applications; Advanz Pharma; Merck; Novartis; SERVIER
Research Funding - NET-España (Inst)
 
Paula Jimenez-Fonseca
Speakers' Bureau - BMS GmbH & Co. KG; Lilly
Other Relationship - IPSEN
 
Belen Llana
No Relationships to Disclose
 
Virginia Pubul
Honoraria - Advanced Accelerator Applications/Novartis
Speakers' Bureau - AAA -NOVARTIS
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis
 
Urbano Anido
Employment - GlaxoSmithKline (I); Leo P (I)
Honoraria - Bayer; Bristol-Myers Squibb; Eisai Europe; Novartis; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; Bayer; Ipsen; Pfizer
Speakers' Bureau - AAA/Endocyte/Novartis; Bristol-Myers Squibb; Ipsen; Merck
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - Ipsen; Novartis; Pfizer; Roche
Other Relationship - LEO Pharma (I)
 
Javier Molina-Cerrillo
Consulting or Advisory Role - Advanced Accelerator Applications; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Pfizer; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Ipsen; Pfizer
Research Funding - Ipsen; Pfizer
Travel, Accommodations, Expenses - Ipsen
 
Maribel del Olmo-García
No Relationships to Disclose
 
Alex Teule
Honoraria - AAA HealthCare; Esteve; Ipsen; Novartis
Consulting or Advisory Role - AAA HealthCare; Esteve
Travel, Accommodations, Expenses - AAA/Endocyte/Novartis
 
Marta Benavent Viñuales
No Relationships to Disclose
 
David Taieb
No Relationships to Disclose
 
Come Lepage
Honoraria - Amgen; Pierre Fabre; SERVIER; Takeda
Consulting or Advisory Role - Advanced Accelerator Applications
Travel, Accommodations, Expenses - Merck Serono; Merck Serono; Pierre Fabre
 
Amandine Beron
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Novartis
 
Catherine Ansquer
Consulting or Advisory Role - Advanced Accelerator Applications; Novartis
Speakers' Bureau - Advanced Accelerator Applications; Novartis
Travel, Accommodations, Expenses - Advanced Accelerator Applications; Novartis
 
Emmanuel Deshayes
Honoraria - Novartis
Consulting or Advisory Role - Novartis
Research Funding - Pi (Inst)
Travel, Accommodations, Expenses - Novartis
 
Eric Baudin
Honoraria - AAA/Endocyte/Novartis; Ipsen
Consulting or Advisory Role - AAA HealthCare; Ipsen
Research Funding - AAA/Endocyte/Novartis (Inst); HRA Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Magalie Haissaguerre
No Relationships to Disclose
 
Thomas Walter
Consulting or Advisory Role - Ipsen; Novartis-adacap; Orano Med; TERUMO
Research Funding - Biodena (Inst); Novartis-adacap (Inst)
Travel, Accommodations, Expenses - Pierre Fabre
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Esteve; Exelixis; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sanofi
Speakers' Bureau - Bayer; Eisai; Esteve; Hutchison MediPharma; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Gilead Sciences (Inst); Ipsen (Inst); Ipsen (Inst); ITM Solucin (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Eisai; Gilead Sciences; Ipsen; Pfizer